Aclidinium bromide/formoterol - Covis Pharma
Alternative Names: Aclidinium bromide/formoterol - AstraZeneca; Aclidinium bromide/formoterol fumarate; BrimicaGenuair; Duaklir Pressair; Duaklir®; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464Latest Information Update: 05 Nov 2023
At a glance
- Originator Laboratorios Almirall
- Developer Allergan; Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical; NIOX
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
- Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 25 Oct 2022 Positive topline efficacy and adverse event data from the phase III AVANT trial in Chronic obstructive pulmonary disease released by Covis Pharma
- 14 Apr 2022 AstraZeneca in collaboration with Paraxel completes a phase III trials in Chronic obstructive pulmonary disease in Philippines, Vietnam, Taiwan, India and China (Inhalation) (NCT03022097)
- 01 Nov 2021 Covis Pharma acquires aclidinium bromide/formoterol from AstraZeneca